Bio-Techne has acquired mdxhealth, a multinational healthcare company specializing in molecular diagnostic information for cancer, for an undisclosed amount. This transaction sees Bio-Techne assume full ownership of mdxhealth, integrating its advanced diagnostic solutions into its existing portfolio. Mdxhealth is recognized for providing actionable molecular diagnostic insights that personalize the diagnosis and treatment of various cancers, with a particular focus on urologic cancers.
Mdxhealth's proprietary technologies include genetic and epigenetic (methylation) assays. These tests assist physicians in diagnosing urologic cancers, assessing the risk of recurrence, and predicting patient response to specific therapies. Key offerings include tests such as Select mdx, Confirm mdx, and the Genomic Prostate Score (GPS), which are crucial for improving the detection and management of aggressive prostate cancer and other urologic diseases. The company maintains its European headquarters in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations in Irvine, California.
This acquisition represents a strategic expansion for Bio-Techne into the precision oncology diagnostics market. By integrating mdxhealth's specialized molecular diagnostic platform, Bio-Techne aims to broaden its diagnostic menu and strengthen its presence in an area critical for personalized medicine. The combination is expected to create synergies by leveraging Bio-Techne's operational capabilities and market reach with mdxhealth's innovative and clinically validated cancer diagnostic tests, particularly those addressing prostate cancer.
The integration of mdxhealth is anticipated to enhance Bio-Techne's position in the global diagnostics landscape, offering a more comprehensive suite of tools for cancer diagnosis and treatment stratification. The combined entity is expected to deliver expanded access to advanced molecular diagnostic solutions, supporting physicians and patients in making more informed decisions regarding cancer care.